 |
|
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim
Clin Mol Hepatol. 2023;29(3):693-704. Published online 2023 Mar 9 DOI: https://doi.org/10.3350/cmh.2022.0330
|
|
Citations to this article as recorded by
 Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Sungho Bea, Hwa Yeon Ko, Jae Hyun Bae, Young Min Cho, Yoosoo Chang, Seungho Ryu, Christopher D Byrne, Ju-Young Shin
Gut.2025; 74(2): 284. CrossRef Influence of glucagon‐like peptide‐1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta‐analysis
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Elodie Bomfim Hyppolito, Erick Figueiredo Saldanha, Rodrigo Vieira Motta
Journal of Gastroenterology and Hepatology.2025; 40(1): 67. CrossRef Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and N
Ruhan Xu, Bo Liu, Xianghai Zhou
Endocrine Practice.2025; 31(4): 521. CrossRef Statin use and liver-related prognosis among patients with MASLD
Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
JHEP Reports.2025; 7(4): 101313. CrossRef Liver diseases: epidemiology, causes, trends and predictions
Can Gan, Yuan Yuan, Haiyuan Shen, Jinhang Gao, Xiangxin Kong, Zhaodi Che, Yangkun Guo, Hua Wang, Erdan Dong, Jia Xiao
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes
Jillian Fetzner, Ebne Rafi
The Journal of Clinical Endocrinology & Metabolism.2025; 110(Supplement): S147. CrossRef Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?
Georgios S. Papaetis, Michalis K. Picolos, Anastasia Sacharidou
Archives of Medical Science – Atherosclerotic Diseases.2025; 10(1): 1. CrossRef Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
Liver International.2025;[Epub] CrossRef Genetic analysis of the correlation between GLP1 action and metabolic liver disease: Insights from Mendelian randomization analysis
Zhiqiang Ma, Binyu Wang, Danpei Li, Xi Chen
Journal of Diabetes Investigation.2025;[Epub] CrossRef Molecular insights into herbal medicines for the treatment of metabolic associated Steatohepatitis
Tamer A. Addissouky
Discover Chemistry.2025;[Epub] CrossRef Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials
Nuttaya Wachiraphansakul, Thanawat Vongchaiudomchoke, Worapaka Manosroi, Surapon Nochaiwong, Saifur R. Chowdhury
PLOS ONE.2024; 19(2): e0297488. CrossRef Metabolic-associated fatty liver disease and sarcopenia: A double whammy
Aditya Viswanath, Sherouk Fouda, Cornelius James Fernandez, Joseph M Pappachan
World Journal of Hepatology.2024; 16(2): 152. CrossRef Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study
Sung Won Chung, Hye-Sung Moon, Hyunjae Shin, Hyein Han, Sehoon Park, Heejin Cho, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Sung-Ho Won, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Dong Ki Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Yoon Jun Kim
Hepatology.2024; 80(3): 633. CrossRef Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho
Clinical and Molecular Hepatology.2024; 30(3): 561. CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
Cancers.2024; 16(18): 3161. CrossRef Metformin: Beyond Type 2 Diabetes Mellitus
Rahnuma Ahmad, Mainul Haque
Cureus.2024;[Epub] CrossRef Polygoni Cuspidati Rhizoma et Radix extract activates TFEB and alleviates hepatic steatosis by promoting autophagy
Chang Li, Chenyu Li, Yi Wang, Sikun You, Ka Yi Man, Zhunming Fan, Qian Yu, Meng Zhang, Kenneth King-yip Cheng, Daniel Kam-Wah Mok, Shun-Wan Chan, Huan Zhang
Life Sciences.2024; 359: 123158. CrossRef Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim
Clinical and Molecular Hepatology.2024; 30(4): 989. CrossRef Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fa
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clinical and Molecular Hepatology.2024; 30(4): 649. CrossRef The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers
Amedeo Lonardo
Expert Review of Clinical Pharmacology.2023; 16(10): 891. CrossRef
|